We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Breakthrough in Fight Against High Priority Pathogen

Credit: Pixabay

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Breakthrough in Fight Against High Priority Pathogen"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

The pathogen Acinetobacter baumannii is one of three highest priority pathogens identified by WHO (World Health Organisation) for which new antibiotics are urgently needed.

Understanding the enzymes that assemble antibiotics which can kill the pathogen is key to altering their structures to target the pathogen more effectively.

Researchers at the University of Warwick have made a breakthrough in understanding the functions and structures of key enzymes in the assembly of an antibiotic with activity against the pathogen, which could enable more effective versions to be created.

One of the WHO's three critical priority pathogens, Acinetobacter baumannii, for which new antibiotics are urgently needed is one step closer to being tackled, as researchers from the Department of Chemistry - University of Warwick have made a breakthrough in understanding the enzymes that assemble the antibiotic enacyloxin.

Acinetobacter baumannii is a pathogen that causes hospital-acquired infections that are very difficult to treat, because they are resistant to most currently available antibiotics.

In a previous paper, researchers at the University of Warwick and Cardiff University showed that a molecule called enacyloxin is effective against Acinetobacter baumannii. However, the molecule needs to be engineered to make it suitable for treating infections caused by the pathogen in humans.

The first step to achieving this is to understand the molecular mechanisms used to assemble enacyloxin by the bacterium that makes it. In their paper 'A dual transacylation mechanism for polyketide synthase chain release in enacyloxin antibiotic biosynthesis' published in the journal Nature Chemistry, the researchers identify the enzymes responsible for joining the two components of the antibiotic together.

The key enzyme in this process was found to be promiscuous, suggesting it could be harnessed to produce structurally modified versions of the antibiotic.

Professor Greg Challis of the Department of Chemistry at the University of Warwick comments: "Being able to alter the structure of the antibiotic will be key in future studies to optimise it for treating infections in humans."

In a second paper, titled 'Structural basis for chain release from the enacyloxin polyketide synthase' also published in Nature Chemistry, the researchers report the structure of the enzyme and that of a companion protein which plays a key role in the process.

Professor Józef Lewandowski also of the Department of Chemistry at the University of Warwick, who co-led the structural study comments: "We found how specific parts of the enzyme and the companion protein recognise each other. Using a computer algorithm to search all publicly available bacterial genomes, we learned that these recognition elements are commonly found in other enzymes and proteins that make antibiotics and anti-cancer drugs."

Professor Challis continues: "Understanding how the enzymes and their companion proteins recognise each other provides important clues about the evolution of antibiotic production in bacteria. It also has the potential to be exploited for creation of new types of molecules not seen in Nature."

Reference: Kosol et al.  2019. Structural basis for chain release from the enacyloxin polyketide synthase. Nature Chemistry. DOI: https://doi.org/10.1038/s41557-019-0335-5

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.